SCHEMBL24112573

SCHEMBL24112573

O=C(O)c1cc2ccc(F)c(Br)c2[nH]1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EIF4A3 P38919 3/20 0.54
HPGD P15428 4/20 0.53
HSD17B10 Q99714 3/20 0.53
ALDH1A1 P00352 3/20 0.53
MEN1 O00255 1/20 0.53
USP2 O75604 1/20 0.53
KMT2A Q03164 1/20 0.53
IDO1 P14902 4/20 0.49
TDO2 P48775 4/20 0.49
KDM4E B2RXH2 3/20 0.46
APEX1 P27695 2/20 0.46
LMNA P02545 2/20 0.46
PDPK1 O15530 1/20 0.46
TSHR P16473 1/20 0.46
NFKB1 P19838 1/20 0.46
CYP2C19 P33261 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
F7 P08709 1/20 0.42
F3 P13726 1/20 0.42
DAO P14920 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29062816 0.85 MAP2K1 (0.43) EIF4A3HPGDHSD17B10ALDH1A1MEN1
SCHEMBL29425105 0.83 EIF4A3 (0.65) EIF4A3HPGDHSD17B10ALDH1A1MEN1
SCHEMBL22395050 0.83 EIF4A3 (0.65) EIF4A3HPGDHSD17B10ALDH1A1MEN1
SCHEMBL28740680 0.80 HPGD (0.53) EIF4A3HPGDHSD17B10ALDH1A1MEN1
SCHEMBL3599395 0.80 EIF4A3 (0.57) EIF4A3HPGDHSD17B10ALDH1A1MEN1
SCHEMBL8959651 0.80 EIF4A3 (0.54) EIF4A3HPGDHSD17B10ALDH1A1MEN1
SCHEMBL25758845 0.78 ALOX15 (0.54) EIF4A3ALDH1A1MEN1KMT2AKDM4E
SCHEMBL21225450 0.77 EIF4A3 (0.50) EIF4A3HPGDHSD17B10ALDH1A1MEN1
SCHEMBL8985908 0.76 HPGD (0.59) EIF4A3HPGDHSD17B10ALDH1A1MEN1
SCHEMBL1145013 0.76 HPGD (0.60) EIF4A3HPGDHSD17B10ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116685576-A Cysteine protease inhibitors and methods of use thereof 美商帕迪斯生物科学公司 2023-09-01 CN disclosed
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-07-06 US disclosed
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-07-06 US disclosed
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-07-06 US disclosed
WO-2021252644-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. (US) 2021-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTRL, CTSL, CTSV EIF4A3 582/4885HPGD 1219/4885HSD17B10 1162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.